Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday

Key Points

• Prelude Therapeutics is expected to report Q3 2026 results before the market opens November 11, with analysts forecasting earnings of $0.004 per share and revenue of $29 million. Its earnings call is scheduled for 8:00 a.m. ET.
• In its prior quarter, Prelude reported a loss of $0.14 per share, beating the consensus estimate of a $0.20 loss; revenue of $5.7 million matched expectations.
• Analyst views are mixed but lean positive: MarketBeat lists a “Moderate Buy” consensus rating and an $8.75 average price target, alongside five Buy, one Hold, and one Sell rating.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of $0.0040 per share and revenue of $29.00 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:00 AM ET.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.06. The company had revenue of $5.70 million for the quarter, compared to analyst estimates of $5.70 million. On average, analysts expect Prelude Therapeutics to post ($0.57) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

Prelude Therapeutics Price Performance

NASDAQ PRLD opened at $3.78 on Wednesday. Prelude Therapeutics has a 1 year low of $1.17 and a 1 year high of $6.83. The company has a market capitalization of $301.64 million, a PE ratio of -5.18 and a beta of 1.22. The company has a fifty day moving average of $4.34 and a two-hundred day moving average of $4.00.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, September 19th. JPMorgan Chase & Co. initiated coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They set an "overweight" rating and a $12.00 price target on the stock. Citigroup reiterated a "market outperform" rating on shares of Prelude Therapeutics in a research note on Wednesday, October 14th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Prelude Therapeutics in a report on Wednesday, July 29th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Prelude Therapeutics in a research report on Tuesday, October 27th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights into cancer biology to design small-molecule therapies intended to target vulnerabilities in tumor cells while potentially improving selectivity over healthy tissue.

Prelude's research and development programs have included targeted therapies aimed at cancer-related proteins and signaling pathways, including cyclin-dependent kinase 9 (CDK9) and other regulators of tumor growth and survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.